Doklady Biochemistry and Biophysics

, Volume 478, Issue 1, pp 18–20 | Cite as

VEGF-R1 as a Potential Molecular Target for Anticancer Therapy

  • E. G. Tyrsina
  • S. I. Nikulitskiy
  • A. N. Inshakov
  • O. O. Ryabaya
Biochemistry, Biophysics, and Molecular Biology


The possibility of using VEGF-R1 receptor for targeted therapy in oncology was investigated. Using the approach to measuring the protein content in intact nuclei of cells, which was developed by us, we showed the presence of this receptor in the nuclei of tumor, but not normal cells. A direct correlation between the level of VEGF-R1 expression in the nucleus and the degree of malignancy of tumor cells, indicating the prognostic value of this parameter, was found. The mechanisms of the functioning of this receptor and the pathways of inhibiting its activity are discussed, and the validity of the selection of VEGF-R1 as a molecular target for anticancer therapy is conformed.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fan, F., Wey, J.S., McCarty, M.F., et al., Oncogen, 2005, vol. 24, pp. 2647–2653.CrossRefGoogle Scholar
  2. 2.
    Wey, J.S., Fan, F., Gray, M.J., et al., Cancer, 2005, vol. 104, pp. 427–438.CrossRefPubMedGoogle Scholar
  3. 3.
    Lee, T.-H., Seng, S., Sekine, M., et al., PLoS Medicine, 2007, vol. 4, no. 6, pp. 1001–1016.CrossRefGoogle Scholar
  4. 4.
    Bhattacharya, R., Ye, X.C., Wang, R., et al., Cancer Res., 2016, vol. 76, no. 10, pp. 3014–3024. doi: 10.1158/0008-5472.CAN-15-1605CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tyrsina, E.G., Nikulitskii, S.I., Inshakov, A.N., and Ryabaya, O.O., Onkoginekologiya, 2016, no. 2, pp. 13–21.Google Scholar
  6. 6.
    Nikulitskii, S.I., Tyrsina, E.G., Inshakov, A.N., and Borovkova, N.B., Ross. Bioterapevt. Zh., 2016, no. 2, pp. 75–80.Google Scholar
  7. 7.
    Szabo, E., Schneider, H., Seystahl, K., et al., Neuro Oncol., 2016, no. 9, pp. 1242–1252. doi: 10.1093/neuonc/now043CrossRefGoogle Scholar
  8. 8.
    Vincent, L., Jin, D.K., Karajannis, M.A., et al., Cancer Res., 2005, vol. 65, pp. 3185–3192.CrossRefPubMedGoogle Scholar
  9. 9.
    Owen, L.A., Uehara, H., Cahoon, J., et al., PLoS ONE, 2013, vol. 7, no. 3, p. e33576.CrossRefGoogle Scholar
  10. 10.
    Broers, J.L.V. and Ramaekers, F.C.S., Adv. Exp. Med. Biol., 2014, vol. 773, pp. 27–48. doi 10.1007/978-1-4899-8032-8_2.2. PMID:24563342CrossRefPubMedGoogle Scholar
  11. 11.
    Chen, M.-K. and Hung, M.-C., Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases, FEBS J., 2015, vol. 282, no. 19, pp. 3693–3721. doi 10.1111/febs.13342CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2018

Authors and Affiliations

  • E. G. Tyrsina
    • 1
  • S. I. Nikulitskiy
    • 1
  • A. N. Inshakov
    • 1
  • O. O. Ryabaya
    • 1
  1. 1.Blokhin Russian Cancer Research CenterMinistry of Health of the Russian FederationMoscowRussia

Personalised recommendations